Steve Lenier

Lessons and Pearls for Moving the Dry Eye Space Forward

Lessons and Pearls for Moving the Dry Eye Space Forward

Before he was chairman of Oyster Point Pharmaceuticals, Michael Ackermann, PhD, worked with a team developing an implantable device. It looked promising, but it was expensive. The team decided to abandon the program, realizing that it was no longer realistic to think the device would receive a high-dollar CPT code...

Read More
Explaining the Explosion in the Dry Eye Space

Explaining the Explosion in the Dry Eye Space

At OIS@AAO 2018, strong attendance at the breakfast breakout session “Evolution of the Dry Eye Market” made a statement about the current level of interest in this topic. As session moderator Preeya Gupta, MD, of Duke University Eye Center said, 10 years ago there wasn’t much of a market for...

Read More
The Gems You’ll Find at OIS@AAO 2018

The Gems You’ll Find at OIS@AAO 2018

Diamonds are emerging as the new 10th anniversary gift. Here’s a look at a few of gems you can mine at the 10th OIS@AAO in two Thursdays, on October 25, at the Marriott Marquis in Chicago a day before the American Academy of Ophthalmology (AAO) annual meeting gets underway. Breakfast...

Read More
Alcon-TrueVision Partnership Delivers on Heads-Up Surgery

Alcon-TrueVision Partnership Delivers on Heads-Up Surgery

At OIS@ASRS 2016, Forrest Fleming, then CEO of TrueVision Systems, announced a new partnership with Alcon. He also introduced the result of that pairing: the Ngenuity 3D Visualization System for digitally assisted vitreoretinal surgery, featuring TrueVision’s heads-up, three-dimensional imaging technology delivered on Alcon’s platform. Fleming said it would be a...

Read More
Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Gene Therapy Treatments Are Filling Some Companies’ Pipelines

Major pharma companies in ophthalmology aren’t the only ones making plays in the gene therapy space, as we reported last week. Mid-size and small companies are also making moves, as evidenced by Astellas Pharma’s acquisition last week of Quethera, which is pursuing a novel gene therapy program for treatment of...

Read More
Big Companies Keep Making Big Plays in Gene Therapy

Big Companies Keep Making Big Plays in Gene Therapy

When Allergan and Editas Medicine disclosed this week that they would move forward on their collaboration to develop a genome editing-medicine for treatment of an inherited retinal disorder, it was the latest move into genetic medicine by big ophthalmology players. Already, Novartis had made two significant moves in the gene...

Read More
Ocular Therapeutix Revamps to Address FDA’s Dextenza Concerns

Ocular Therapeutix Revamps to Address FDA’s Dextenza Concerns

When Ocular Therapeutix resubmitted its new drug application for Dextenza late in June, it represented a milestone in the company’s effort to essentially reshape itself from a device to a pharma firm. And this time, Ocular thinks it has come up with the formula to gain FDA approval. This latest...

Read More
A String of Pearls for Navigating the FDA

A String of Pearls for Navigating the FDA

WASHINGTON, DC – Having OIS@ASCRS 2018 here provided the perfect opportunity for representatives of the US Food and Drug Administration to impart wisdom on how attendees can help streamline application and approval processes for their innovations. The OIS@ASCRS Master Class, held the morning after OIS@ASCRS, featured staff members from the...

Read More
Digital Health: Threat or Opportunity?

Masters of Industry: Digital Health – Threat or Opportunity?

The “Masters of the Industry” panel at the recent OIS@ASCRS 2018 in Washington, DC, put into context the impact digital health is having on eye care practices, especially in this era of practice consolidation as private equity buys them up. As Tom Frinzi, worldwide president, surgical, for Johnson & Johnson...

Read More
More Approaches for AI in Retina Emerge

AI and Retinal Disease: More Approaches Keep Emerging

Artificial intelligence (AI) is making waves in diagnosing retinal disease. Computers with this technology can be quicker and less expensive than a doctor, but can they be trusted to get it right? New AI methodologies that aim to answer this question seem to be emerging weekly. Just a few weeks...

Read More
Emerging Gene Therapy Candidate Advances

MeiraGTx Gene Therapy Candidate for Achromatopsia Moves Forward

An emerging gene therapy candidate for the treatment of inherited eye disease has taken a step forward with MeiraGTx announcing that it has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for A002, which is for the treatment of achromatopsia (ACHM) due to mutations in the CNGB3...

Read More
Allergan Ready for a Future of Generic Competitors

Allergan Ready for a Future of Generic Competitors

At the 36th annual JP Morgan Healthcare Conference in San Francisco, Allergan CEO Brent Saunders said a disconnect exists between the company’s 2017 results and its stock price. Even though the stock Monday closed about 25% below its one-year high, he told the JPM attendees that Allergan stock is undervalued,...

Read More